Mineralys Therapeutics In... (MLYS)
Mineralys Therapeutics Statistics
Share Statistics
Mineralys Therapeutics has 64.88M shares outstanding. The number of shares has increased by 26.46% in one year.
| Shares Outstanding | 64.88M |
| Shares Change (YoY) | 26.46% |
| Shares Change (QoQ) | 26.15% |
| Owned by Institutions (%) | 91.99% |
| Shares Floating | 38.28M |
| Failed to Deliver (FTD) Shares | 34.94K |
| FTD / Avg. Volume | 3.13% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -3.36 and the forward PE ratio is -3.45. Mineralys Therapeutics's PEG ratio is -0.04.
| PE Ratio | -3.36 |
| Forward PE | -3.45 |
| PS Ratio | 0 |
| Forward PS | 1.4 |
| PB Ratio | 3.12 |
| P/FCF Ratio | -3.59 |
| PEG Ratio | -0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Mineralys Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.02, with a Debt / Equity ratio of 0.
| Current Ratio | 14.02 |
| Quick Ratio | 14.02 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.49M |
| Employee Count | 51 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 19.1% in the last 52 weeks. The beta is -0.39, so Mineralys Therapeutics's price volatility has been lower than the market average.
| Beta | -0.39 |
| 52-Week Price Change | 19.1% |
| 50-Day Moving Average | 12.62 |
| 200-Day Moving Average | 12.32 |
| Relative Strength Index (RSI) | 51 |
| Average Volume (20 Days) | 1.11M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -192.4M |
| Net Income | -177.81M |
| EBITDA | -192.4M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.66 |
Balance Sheet
The company has 114.09M in cash and 0 in debt, giving a net cash position of 114.09M.
| Cash & Cash Equivalents | 114.09M |
| Total Debt | 0 |
| Net Cash | 114.09M |
| Retained Earnings | -302.52M |
| Total Assets | 205.9M |
| Working Capital | 190.71M |
Cash Flow
In the last 12 months, operating cash flow was -166.31M and capital expenditures -96K, giving a free cash flow of -166.41M.
| Operating Cash Flow | -166.31M |
| Capital Expenditures | -96K |
| Free Cash Flow | -166.41M |
| FCF Per Share | -3.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MLYS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MLYS is $33, which is 143.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $33 |
| Price Target Difference | 143.9% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 31.08 |
| Piotroski F-Score | 1 |